COVID-19
Conditions
Interventions
None listed
Sponsors
The Japanese Circulation Society
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet the criteria for enrollment and consent to participate in the "Survey on the Sequelae of COVID-19 (for patients with moderate or severe disease)," the main study led by the Japanese Respiratory Society, and who meet either of the following (1), (2), or (3). (1) High-sensitivity troponin positivity confirmed at least once during hospitalization or at the 3-month discharge follow-up (2) A high-sensitivity troponin level recorded during hospitalization or up to 3 months after discharge that is confirmed to have increased by 50% or more from the time of hospitalization (or 150% or more of the sensitive concentration if the level at the time of hospitalization was less than the sensitive concentration) (3) BNP or NT-proBNP recorded during hospitalization or up to 3 months after discharge, with BNP>=100 pg/mL or NT-proBNP >=300 pg/mL * Reference; Inclusion criteria for the primary research Patients who meet the following criteria will be eligible. (1) Patients with moderate or severe disease according to the COVID-19 Clinical Practice Guidelines (2) Patients who have been hospitalized for COVID-19 and have already been discharged or are expected to be discharged by December 31, 2021. (3) Patients who have given consent
Exclusion criteria
Exclusion criteria: (1) A history of coronary artery disease (myocardial infarction or angina pectoris) or heart failure has been noted prior to admission. 2) Patients who are not suitable for contrast-enhanced MRI (claustrophobia, after implantation of metal in the body with MRI contraindication, severe renal dysfunction [eGFR<30mL/min/1.73m2], history of serious adverse reaction to gadolinium contrast agent (anaphylactic reaction), pregnant women). * Reference; Exclusion criteria for the primary research Subjects will be excluded from this study if they meet any of the following criteria (1) Patients under 20 years of age (2) Cases judged ineligible by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of cardiac injury associated with COVID-19 defined in the presence of at least one of the followings: 1. Presence of fibrosis in left or right ventricular detected by enhanced CMR 2. LVEF <50% and/or RVEF <45% measured by CMR 3. Pericardial thickening or enhancement | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Comparing the following parameters between study subjects and age, gender, and risk-factors matched control; - Strain analysis using CMR for both LV and RV - Presence of myocardial LGE in LV or RV - Abnormal native T1 and extracellular volume fraction (ECV) 2. In patients with available echocardiography imaging, accordance in LV/RV function between CMR and echocardiography. 3. Association between finding of lung fibrosis (using categories of normal/GGO/consolidation/emphysema) in CT scan and cardiac findings evaluated by CMR. | — |
Countries
Japan
Contacts
Public ContactYuya Matsue
Juntendo University Hospital Cardiology
Outcome results
None listed